



This analysis examines the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). The analysis focuses only on the technologies that passed the standard 90 days period and bases on the data published by the NHIFA on December 06, 2017. The validity of published data has not been investigated by Healthware.


## Number of the ongoing submission procedures by reimbursement category (brands)




In 28 SKUs the exact indications are unknown.



## Average procedure length by reimbursement category (days)



## Average procedure length by ATC main groups (days)




## Number of the ongoing submission procedures by ATC5 codes

ATC5	Name	Brands	SKUs
L01XE	Protein kinase inhibitors	8	17
L01XC	Monoclonal antibodies	7	14
L04AA	Selective immunosuppressants	4	6
L04AC	Interleukin inhibitors	4	9
L01XX	Other antineoplastic agents	3	4
R03DX	Other systemic drugs for obstructive airway diseases	3	3
B01AC	Platelet aggregation inhibitors excl. heparin	2	3
B02BD	Blood coagulation factors	2	6
C09DX	Angiotensin II antagonists, other combinations	2	8
C10AX	Other lipid modifying agents	2	2
L01BC	Pyrimidine analogues	2	3
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors	2	3
S01LA	Antineovascularisation agents	2	2
A04AA	Serotonin (5HT3) antagonists	1	1
A10AE	Insulins and analogues for injection, long-acting	1	1
B02AB	Heparin group	1	1
C02KX	Antihypertensives for pulmonary arterial hypertension	1	1
C07AA	Beta blocking agents, non-selective	1	1
H05BX	Other anti-parathyroid agents	1	1
J05A	Direct acting antivirals	1	1
J05AR	Antivirals for treatment of HIV infections, combinations	1	1
J06BA	Immunoglobulins, normal human	1	1
L02BX	Other hormone antagonists and related agents	1	1
L03AB	Interferons	1	1
L04AX	Other immunosuppressants	1	1
N01AH	Opioid anesthetics	1	1
S01XA	Other ophthalmologicals	1	1
V04CJ	Tests for thyroidea function	1	1
<b>Total</b>		<b>58</b>	<b>95</b>


Source: Healthware analysis based on NHIFA data

## Top 3 applicants by the number of brands and SKUs



Source: Healthware analysis based on NHIFA data

## Top 3 ATC main group by the number of brands and SKUs




L - Antineoplastic and immunomodulating agents  
C - Cardiovascular system  
B - Blood and blood forming organs

During the NHIFA co-ordinated period, the financing structure for the technology will be determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision is taken by a Committee coordinated by the Ministry.

- 65% are waiting for the final decision more than 90 days.
- NHIFA made a positive preliminary decision on 78% of the submissions.
- The average procedure time of the analyzed products is 386 days (min-max: 102 and 894 days).
- The average procedure time of NHIFA is 271 days (min-max: 21 and 882 days).
- The average procedure time of MoHC is 151 days (min-max: 12 and 525 days).

Typically the average waiting time is longer in case of products which claimed a new indication point and which are innovative products with new mode of action (e.g. PCSK9 inhibitors, targeted oncology therapies, immunotherapies). The most frequent indications are the neoplastic diseases and within that the non-small cell lung cancer.

With further questions, please contact us!



<sup>1</sup> NHIFA: National Health Insurance Fund of Hungary  
<sup>2</sup> Standard official process period of NHIFA